BTIG Rates SOPHiA GENETICS (SOPH) buy, $8 Price Target

BTIG analyst Mark Massaro reaffirms a positive outlook on SOPH, a 63.93% upside from the current price.

By EarningsIQ Research Desk · Published Jun 15, 2026, 8:01 AM EDT · Updated Jun 16, 2026, 1:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG rated SOPHiA GENETICS SA ($SOPH) "buy" with a $8 price target on June 15, 2026.

Since the rating, $SOPH is up 6.6% after 1 week, up 15.2% after 1 month and up 34.3% to date (from the $5.01 close on Jun 15, 2026).

SOPH SOPHiA GENETICS SA

$6.73 +44.11% year to date

Daily close · Oct 16, 2026

Key Points

BTIG analyst Mark Massaro reiterated a Buy rating on SOPH with a target price of $8 on June 15, 2026.
BTIG's $8 price target implies 63.93% upside from SOPHiA GENETICS SA's ($SOPH) current $4.88 share price.
SOPH shares are currently trading around $4.88, reflecting the analyst's confidence despite the stock's lower price.
The reaffirmation by BTIG comes amid insider transactions and other institutional activities in SOPH's stock.

Get $SOPH trade alerts by text

We text you when insiders, Congress or big funds trade $SOPH. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated SOPHiA GENETICS SA alert may contain errors. Disclosures

BTIG's analyst Mark Massaro has reiterated a Buy rating for SOPH, setting a price target of $8. This update was made on June 15, 2026, as the stock currently trades around $4.88. Massaro's reaffirmation reflects continued confidence in SOPH's potential upside.

Other Institutional Activity in SOPH

Several institutional investors have shown interest in SOPH. Generation Investment Management LLP holds 6,789,560 shares valued at approximately $33.6 million, while Akre Capital Management LLC owns 3,719,140 shares worth about $18.4 million. Banque Pictet & Cie SA holds 2,208,280 shares valued at roughly $10.9 million. Soleus Capital Management, L.P. significantly increased its stake by adding 1,850,000 shares, bringing its total to 1,850,000 shares valued at about $9.2 million. Royce & Associates LP also boosted its holdings, adding 1,386,055 shares to reach 1,816,312 shares, valued at approximately $9 million.

SOPHiA GENETICS SA Stock Down 33.1%

Shares of SOPH are trading near $4.88. The stock has seen various insider activities and institutional interests, indicating a dynamic market environment.

12-month forecast

$SOPH price target

SOPHiA GENETICS SA daily closes and this analyst's $8 target. Not advice.

Insider Buying and Selling at SOPHiA GENETICS SA

There have been notable insider transactions at SOPH. On June 10, 2026, CEO Jurgi Camblong sold 8,500 shares at $5.24 each, under a planned sale. Earlier, on June 5, 2026, CFO George Cardoza purchased 20,000 shares at $4.95 apiece. Chief Medical Officer Philippe Menu sold 5,000 shares on May 26, 2026, at $4.95 each, also as part of a planned sale.

Analysts Set New Price Targets

On June 15, 2026, BTIG reiterated its Buy rating for SOPH, setting a price target of $8. Previously, the firm maintained the same rating and target on April 15, 2026. Other analysts like Guggenheim have also maintained a Buy rating with a target of $7 back in January 2026.

Bottom Line

BTIG's reaffirmation of SOPH with a Buy rating and an $8 target highlights continued confidence in the company's future prospects. The stock's current trading price of $4.88 suggests potential upside, as reflected by both institutional activity and insider transactions. Investors will watch for further developments as SOPH continues to attract attention from analysts and major funds.